Mary Wilson
Well-known member
Journal pre-proofs are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication
13 April 2022
https://doi.org/10.1016/j.medj.2022.04.001
AravindNatarajan[SUP]1[/SUP][SUP]2[/SUP][SUP]∗ [/SUP]SoumayaZlitni[SUP]1[/SUP][SUP]2[/SUP][SUP]∗ [/SUP]Erin F.Brooks[SUP]2[/SUP][SUP]∗ [/SUP]SummerE.Vance[SUP]2[/SUP][SUP]∗ [/SUP]AlexDahlen[SUP]3 [/SUP]HaleyHedlin[SUP]3 [/SUP]Ryan M.Park AlvinHan[SUP]4 [/SUP]Danica T.Schmidtke[SUP]4 [/SUP]RenuVerma[SUP]5 [/SUP]Karen B.Jacobson[SUP]5 [/SUP]JulieParsonnet[SUP]6[/SUP][SUP]7 [/SUP]Hector F.Bonilla[SUP]6 [/SUP]UpinderSingh[SUP]5 [/SUP]Benjamin A.Pinsky[SUP]5[/SUP][SUP]8 [/SUP]Jason R.Andrews[SUP]5 [/SUP]PrasannaJagannathan[SUP]4[/SUP][SUP]6 [/SUP]Ami S.Bhatt[SUP]1[/SUP][SUP]2[/SUP]
Highlights
1.Approximately half of COVID-19 patients shed fecal RNA in the week after infection
2.4% patients with COVID-19 shed fecal viral RNA 10 months after diagnosis.
3.Presence of fecal SARS-CoV-2 RNA is associated with gastrointestinal symptoms.
4.SARS-CoV-2 likely infects gastrointestinal tissue.
Abstract
Background:
COVID-19 manifests with respiratory, systemic, and gastrointestinal (GI)symptoms.1,2 SARS-CoV-2 RNA is detected in respiratory and fecal samples, and recent reports demonstrate viral replication in both the lung and intestinal tissue.3–5 Although much is known about early fecal RNA shedding, little is known about the long term shedding, especially in those with mild COVID-19. Furthermore, most reports of fecal RNA shedding do not correlate these findings with GI symptoms.
Methods:
We analyze the dynamics of fecal RNA shedding up to 10 months after COVID-19 diagnosis in 113 individuals with mild to moderate disease. We also correlate shedding with disease symptoms.
Findings:
Fecal SARS-CoV-2 RNA is detected in 49.2% [95% Confidence interval = 38.2%-60.3%] of participants within the first week after diagnosis. Whereas there was no ongoing oropharyngeal SARS-CoV-2 RNA shedding in subjects at and after 4 months, 12.7% [8.5%-18.4%] of participants continued to shed SARS-CoV-2 RNA in the feces at 4 months after diagnosis and 3.8% [2.0%-7.3%] shed at 7 months. Finally, we find that GI symptoms (abdominal pain, nausea, vomiting) are associated with fecal shedding of SARS-CoV-2 RNA.
Conclusions:
The extended presence of viral RNA in feces, but not respiratory samples, along with the association of fecal viral RNA shedding with GI symptoms suggest that SARS-CoV-2 infects the GI tract, and that this infection can be prolonged in a subset of individuals with COVID-19.
https://pdf.sciencedirectassets.com...691d944a072b855-45d4a173dcc0gxrqa&type=client
13 April 2022
https://doi.org/10.1016/j.medj.2022.04.001
AravindNatarajan[SUP]1[/SUP][SUP]2[/SUP][SUP]∗ [/SUP]SoumayaZlitni[SUP]1[/SUP][SUP]2[/SUP][SUP]∗ [/SUP]Erin F.Brooks[SUP]2[/SUP][SUP]∗ [/SUP]SummerE.Vance[SUP]2[/SUP][SUP]∗ [/SUP]AlexDahlen[SUP]3 [/SUP]HaleyHedlin[SUP]3 [/SUP]Ryan M.Park AlvinHan[SUP]4 [/SUP]Danica T.Schmidtke[SUP]4 [/SUP]RenuVerma[SUP]5 [/SUP]Karen B.Jacobson[SUP]5 [/SUP]JulieParsonnet[SUP]6[/SUP][SUP]7 [/SUP]Hector F.Bonilla[SUP]6 [/SUP]UpinderSingh[SUP]5 [/SUP]Benjamin A.Pinsky[SUP]5[/SUP][SUP]8 [/SUP]Jason R.Andrews[SUP]5 [/SUP]PrasannaJagannathan[SUP]4[/SUP][SUP]6 [/SUP]Ami S.Bhatt[SUP]1[/SUP][SUP]2[/SUP]
Highlights
1.Approximately half of COVID-19 patients shed fecal RNA in the week after infection
2.4% patients with COVID-19 shed fecal viral RNA 10 months after diagnosis.
3.Presence of fecal SARS-CoV-2 RNA is associated with gastrointestinal symptoms.
4.SARS-CoV-2 likely infects gastrointestinal tissue.
Abstract
Background:
COVID-19 manifests with respiratory, systemic, and gastrointestinal (GI)symptoms.1,2 SARS-CoV-2 RNA is detected in respiratory and fecal samples, and recent reports demonstrate viral replication in both the lung and intestinal tissue.3–5 Although much is known about early fecal RNA shedding, little is known about the long term shedding, especially in those with mild COVID-19. Furthermore, most reports of fecal RNA shedding do not correlate these findings with GI symptoms.
Methods:
We analyze the dynamics of fecal RNA shedding up to 10 months after COVID-19 diagnosis in 113 individuals with mild to moderate disease. We also correlate shedding with disease symptoms.
Findings:
Fecal SARS-CoV-2 RNA is detected in 49.2% [95% Confidence interval = 38.2%-60.3%] of participants within the first week after diagnosis. Whereas there was no ongoing oropharyngeal SARS-CoV-2 RNA shedding in subjects at and after 4 months, 12.7% [8.5%-18.4%] of participants continued to shed SARS-CoV-2 RNA in the feces at 4 months after diagnosis and 3.8% [2.0%-7.3%] shed at 7 months. Finally, we find that GI symptoms (abdominal pain, nausea, vomiting) are associated with fecal shedding of SARS-CoV-2 RNA.
Conclusions:
The extended presence of viral RNA in feces, but not respiratory samples, along with the association of fecal viral RNA shedding with GI symptoms suggest that SARS-CoV-2 infects the GI tract, and that this infection can be prolonged in a subset of individuals with COVID-19.
https://pdf.sciencedirectassets.com...691d944a072b855-45d4a173dcc0gxrqa&type=client